Biomea Fusion (NASDAQ:BMEA – Free Report) had its price objective boosted by Scotiabank from $21.00 to $41.00 in a report issued on Friday morning, Benzinga reports. Scotiabank currently has a sector outperform rating on the stock.
Other research analysts also recently issued research reports about the company. Oppenheimer dropped their price objective on Biomea Fusion from $70.00 to $60.00 and set an outperform rating on the stock in a report on Thursday, May 30th. Truist Financial raised shares of Biomea Fusion from a hold rating to a buy rating and set a $54.00 price objective on the stock in a report on Friday. Citigroup lowered their target price on shares of Biomea Fusion from $45.00 to $22.00 and set a buy rating for the company in a report on Tuesday, August 27th. HC Wainwright lifted their price target on shares of Biomea Fusion from $15.00 to $40.00 and gave the stock a buy rating in a research note on Friday. Finally, Piper Sandler reduced their price target on shares of Biomea Fusion from $45.00 to $10.00 and set an overweight rating for the company in a research report on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biomea Fusion has an average rating of Moderate Buy and a consensus price target of $29.40.
Check Out Our Latest Research Report on BMEA
Biomea Fusion Price Performance
Biomea Fusion (NASDAQ:BMEA – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported ($1.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.03). Equities research analysts anticipate that Biomea Fusion will post -4.09 earnings per share for the current year.
Institutional Trading of Biomea Fusion
A number of hedge funds and other institutional investors have recently made changes to their positions in BMEA. Capstone Investment Advisors LLC purchased a new stake in shares of Biomea Fusion during the 1st quarter worth about $182,000. Centaurus Financial Inc. bought a new stake in Biomea Fusion in the fourth quarter valued at $102,000. PNC Financial Services Group Inc. bought a new stake in shares of Biomea Fusion in the 4th quarter worth about $116,000. SG Americas Securities LLC acquired a new stake in shares of Biomea Fusion during the first quarter worth approximately $462,000. Finally, Griffin Asset Management Inc. increased its holdings in Biomea Fusion by 39.4% during the 1st quarter. Griffin Asset Management Inc. now owns 37,890 shares of the company’s stock valued at $566,000 after purchasing an additional 10,700 shares in the last quarter. 96.72% of the stock is currently owned by institutional investors.
About Biomea Fusion
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Read More
- Five stocks we like better than Biomea Fusion
- Market Cap Calculator: How to Calculate Market Cap
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to buy stock: A step-by-step guide for beginners
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.